GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » ROE % Adjusted to Book Value

SynAct Pharma AB (OSTO:SYNACT) ROE % Adjusted to Book Value : -30.03% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB ROE % Adjusted to Book Value?

SynAct Pharma AB's ROE % for the quarter that ended in Mar. 2024 was -60.66%. SynAct Pharma AB's PB Ratio for the quarter that ended in Mar. 2024 was 2.02. SynAct Pharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -30.03%.


SynAct Pharma AB ROE % Adjusted to Book Value Historical Data

The historical data trend for SynAct Pharma AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB ROE % Adjusted to Book Value Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -23.12 -2.78 -2.13 -7.05 -80.11

SynAct Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.86 -6.96 -20.85 -105.40 -30.03

Competitive Comparison of SynAct Pharma AB's ROE % Adjusted to Book Value

For the Biotechnology subindustry, SynAct Pharma AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SynAct Pharma AB's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's ROE % Adjusted to Book Value falls into.



SynAct Pharma AB ROE % Adjusted to Book Value Calculation

SynAct Pharma AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-142.59% / 1.78
=-80.11%

SynAct Pharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-60.66% / 2.02
=-30.03%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SynAct Pharma AB ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


SynAct Pharma AB (OSTO:SYNACT) Business Description

Traded in Other Exchanges
Address
Sheelevagen 2, Lund, SWE, 223 81
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines